59 results
424B5
ARQT
Arcutis Biotherapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:06pm
inflammation and immunology, to address the significant need for effective chronic treatments in immuno-dermatology. Our initial development and commercial focus … to show significant symptomatic improvement, maintain a low risk of toxicity or side effects, and are suitable for chronic use on all areas of the body
424B5
ARQT
Arcutis Biotherapeutics Inc
28 Feb 24
Prospectus supplement for primary offering
4:21pm
to leverage developments in other fields of medicine, particularly inflammation and immunology, to address the significant need for effective chronic … or side effects, and are suitable for chronic use on all areas of the body. Based on market research and our internal estimates, we estimate
424B5
ARQT
Arcutis Biotherapeutics Inc
23 Oct 23
Prospectus supplement for primary offering
4:23pm
the significant need for effective chronic treatments in immuno-dermatology. Our initial development and commercial focus is to address patients … improvement, maintain a low risk of toxicity or side effects, and are suitable for chronic use on all areas of the body. Based on market research
424B5
ARQT
Arcutis Biotherapeutics Inc
19 Oct 23
Prospectus supplement for primary offering
4:15pm
and immunology, to address the significant need for effective chronic treatments in immuno-dermatology. Our initial development and commercial focus … significant symptomatic improvement, maintain a low risk of toxicity or side effects, and are suitable for chronic use on all areas of the body. Based
8-K
EX-99.1
9evoaz1f4
19 Oct 23
Results of Operations and Financial Condition
4:02pm
8-K
EX-99.1
lx9641na
9 May 23
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
EX-99.1
qhlh3brxvzm c2t
16 Dec 22
Other Events
4:03pm
8-K
EX-99.1
uwdi9afsrr3sxja724
8 Nov 22
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
l9njd46bd tssskm
7 Sep 22
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-99.1
fmojvb ifjsngbu2o
4 Aug 22
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
5:25pm
424B5
wigqz
4 Aug 22
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
se8vwp 3k1cookxr13b
2 Aug 22
Fda Approves Arcutis’ Zoryve™ (Roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis In Individuals Age 12 and Older
4:01pm
8-K
EX-99.2
boflbmar6102r0
9 Jun 22
Other Events
4:31pm
8-K
EX-99.1
put15wcc96z
9 Jun 22
Other Events
4:31pm
8-K
EX-99.1
o4phefm8b dz8kod5ch
5 May 22
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
4:04pm